Compare AMCI & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMCI | LUNG |
|---|---|---|
| Founded | 2021 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Industrial Specialties |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 110.5M | 97.1M |
| IPO Year | 2022 | 2020 |
| Metric | AMCI | LUNG |
|---|---|---|
| Price | $3.25 | $1.97 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $5.38 |
| AVG Volume (30 Days) | 98.2K | ★ 283.1K |
| Earning Date | 04-20-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.64 |
| EPS | ★ N/A | N/A |
| Revenue | $5,980,847.00 | ★ $90,497,000.00 |
| Revenue This Year | N/A | $2.48 |
| Revenue Next Year | N/A | $18.46 |
| P/E Ratio | $476.00 | ★ N/A |
| Revenue Growth | N/A | ★ 8.01 |
| 52 Week Low | $2.94 | $1.13 |
| 52 Week High | $15.75 | $2.89 |
| Indicator | AMCI | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 38.68 | 46.94 |
| Support Level | $3.01 | $1.20 |
| Resistance Level | $3.99 | $2.12 |
| Average True Range (ATR) | 0.27 | 0.11 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 33.77 | 56.53 |
AMC Robotics Corp is a technology solutions company that offers AI-powered smart security and robotics solutions. It currently sells smart hardware products designed for residential and commercial use, including smart cameras, driving recorders, action cameras, and Retina K cameras, which are marketed under the YI brand. AMC Robotics is also engaged in developing additional hardware products and technology capabilities, including IoT-enabled devices, AI-based features, wearable devices, and AI robotics. Using its technological capabilities, the company is developing robotic dogs, robotic arms, and robotic unloading systems, offering smart solutions for the logistics and warehousing sectors. It has two primary operating segments: North America, which generates maximum revenue, and Europe.
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.